AARTIPHARM

Aarti Pharmalabs has reported disappointing financial results for the quarter ending June 2025, with significant declines across key performance metrics. The company's net sales for the quarter stood at Rs 386.19 crore, reflecting a sharp decrease of 27.0% compared to the average net sales of Rs 528.77 crore over the previous four quarters. This marks the lowest sales figure recorded in the last five quarters. Profit Before Tax (PBT) also experienced a notable decline, falling to Rs 63.85 crore, a decrease of 27.1% from the average PBT of Rs 87.65 crore in the prior four quarters. Similarly, Profit After Tax (PAT) dropped to Rs 49.50 crore, down 27.3% from the average of Rs 68.10 crore. Additionally, the company's earnings per share (EPS) reached its lowest point in five quarters at Rs 5.46, indicating declining profitability. The debt-equity ratio has risen to 0.21 times, the highest in the last five half-yearly periods, suggesting increased borrowing to support operations. Overall, Aarti Pharmalabs is facing significant challenges in its financial performance.